Component

The CYP2C9 isoleucine 359 leucine variant, CYP2C9*3

The CYP2C9 isoleucine 359 leucine variant, CYP2C9*3. Species, exposure and limitations are retained in each linked claim.

1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What it acts on

  1. Population mean S-ibuprofen clearances were 3.25, 2.38 and 1.52 litres per hour in carriers of CYP2C9 genotypes *1/*1, *1/*3 and *3/*3 respectively while the *2 variant had no significant effect, and ex vivo formation of thromboxane B2 reflecting cyclooxygenase-1 inhibition depended significantly on the polymorphism, with maximal inhibition and the area under the effect-time curve larger in carriers of the slow genotypes, the same trend holding for prostaglandin E2.

    The CYP2C9 isoleucine 359 leucine variant, CYP2C9*3 → S(+)-ibuprofen source_derived_draftungraded
    Experimental context and source evidence
    availability_state
    machinery_impairment Imported condition classification; unverified.
    evidence_span
    {"source_cache": "artifacts/ibuprofen-research/12152005.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "314477c44dbb699b0fe3d9ab14eb7da427d88538177b4e4267ef0ad25fd407da", "start_char": 0, "end_char": 1822, "text_sha256": "314477c44dbb699b0fe3d9ab14eb7da427d88538177b4e4267ef0ad25fd407da"}
    experimental_model
    Population pharmacokinetic study in 21 healthy volunteers across all combinations of CYP2C9 variants
    exposure
    600 milligrams oral racemic ibuprofen, with thromboxane B2 and prostaglandin E2 measured ex vivo
    limitations
    Links a genotype to both the drug level and the enzyme effect in the same subjects. Twenty-one volunteers spread across genotype groups, so each group is small.
    nutrient_topic
    Ibuprofen research collection; topical membership is not evidence of a direct clinical effect, and the racemate is recorded separately from each of its two enantiomers. · Ibuprofen
    organism
    Human
    plain_language
    People who clear the active half slowly get both more drug and more effect from the same tablet.
    primary_references
    [ibu-p12152005] Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2. (2002). https://pubmed.ncbi.nlm.nih.gov/12152005/ DOI: 10.1067/mcp.2002.125726
    tissue_or_cell_type
    Plasma, platelets and monocytes
    trigger_kind
    machinery_impairment Imported condition classification; unverified.

    Ibuprofen: the enantiomer that works, the one that was called inactive, the one-way chemistry that turns one into the other, and the targets that are not cyclooxygenase (2026-09-22) · lines 214–225

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Population pharmacokinetic study in 21 healthy volunteers across all combinations of CYP2C9 variants · source_derived_draft · unverified_draft

    ### ibu-slow-clearance-more-effect Population mean S-ibuprofen clearances were 3.25, 2.38 and 1.52 litres per hour in carriers of CYP2C9 genotypes *1/*1, *1/*3 and *3/*3 respectively while the *2 variant had no significant effect, and ex vivo formation of thromboxane B2 reflecting cyclooxygenase-1 inhibition depended significantly on the polymorphism, with maximal inhibition and the area under the effect-time curve larger in carriers of the slow genotypes, the same trend holding for prostaglandin E2. Condition category: machinery_impairment nutrient_topic: Ibuprofen research collection; topical membership is not evidence of a direct clinical effect, and the racemate is recorded separately from each of its two enantiomers. plain_language: People who clear the active half slowly get both more drug and more effect from the same tablet. organism: Human tissue_or_cell_type: Plasma, platelets and monocytes experimental_model: Population pharmacokinetic study in 21 healthy volunteers across all combinations of CYP2C9 variants limitations: Links a genotype to both the drug level and the enzyme effect in the same subjects. Twenty-one volunteers spread across genotype groups, so each group is small. exposure: 600 milligrams oral racemic ibuprofen, with thromboxane B2 and prostaglandin E2 measured ex vivo evidence_span: {"source_cache": "artifacts/ibuprofen-research/12152005.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "314477c44dbb699b0fe3d9ab14eb7da427d88538177b4e4267ef0ad25fd407da", "start_char": 0, "end_char": 1822, "text_sha256": "314477c44dbb699b0fe3d9ab14eb7da427d88538177b4e4267ef0ad25fd407da"} [ibu-p12152005] Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2. (2002). https://pubmed.ncbi.nlm.nih.gov/12152005/ DOI: 10.1067/mcp.2002.125726
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards